Basaglar and Emphysema - a phase IV clinical study of FDA data

Summary:

Emphysema is reported as a side effect among people who take Basaglar (insulin glargine), especially for people who are female, 50-59 old, also take Opsumit, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Emphysema when taking Basaglar. It is created by eHealthMe based on reports of 19,751 people who have side effects when taking Basaglar from the FDA, and is updated regularly.

What is Basaglar?

Basaglar has active ingredients of insulin glargine. eHealthMe is studying from 19,807 Basaglar users. Check the latest studies of Basaglar.

What is Emphysema?

Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs) is found to be associated with 1,063 drugs and 1,098 conditions by eHealthMe. Check the latest studies of Emphysema.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

19,751 people reported to have side effects when taking Basaglar.
Among them, 11 people (0.06%) have Emphysema.

Among these 11 people:

What is the gender of people who have Emphysema when taking Basaglar? *

female: 90.91 %
male: 9.09 %

What is the age of people who have Emphysema when taking Basaglar? *

What are other drugs people take besides Basaglar? *

What are other side effects people have besides Emphysema? *

Dyspnea (difficult or laboured breathing): 4 people, 36.36%
Feeling Abnormal: 4 people, 36.36%
Headache (pain in head): 4 people, 36.36%
Pain: 4 people, 36.36%
Drug Intolerance (drug sensitivity): 3 people, 27.27%
Paranasal Sinus Discomfort: 3 people, 27.27%
Biopsy Lung Abnormal: 3 people, 27.27%
Influenza Like Illness: 3 people, 27.27%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 18.18%
Chest Pain: 2 people, 18.18%

What are the existing conditions these people have? *

Type 2 Diabetes: 4 people, 36.36%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 4 people, 36.36%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 9.09%
High Blood Pressure: 1 person, 9.09%
Diabetes: 1 person, 9.09%
Depression: 1 person, 9.09%
Bipolar Disorder (mood disorder): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Basaglar and have Emphysema?

- Check whether Emphysema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Basaglar:

Basaglar (19,807 reports)

Emphysema treatments and more:

Emphysema (29,685 reports)

Browse all side effects of Basaglar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Emphysema:

Emphysema (1,063 drugs)

Browse all the conditions that are associated with Emphysema:

Emphysema (1,098 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin glargine (the active ingredients of Basaglar) and Basaglar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.